23rd, April 2019
Protein Alternatives S.L. (PROALT) has begun the clinical validation study of its blood-based diagnostic test for colorectal cancer in Luminex® and ELISA-based formats. COLODETECT® test is based on detecting in blood the autoantibodies (AAbs) generated by the human body against proteins related to the colorectal cancer tumor, known as tumor-associated antigens (TAAs) or neoantigens. The simplicity of COLODETECT® will allow the screening of large population at risk.
More than 4,200 samples were collected from nine different hospitals in Spain.
Patient’s samples will be tested with the prototypes developed:
We are right in our schedule with the validation study and are confident that we will be able to launch COLODETECT® onto the market as planned at the end of 2019 beginning of 2020.
About Protein Alternatives:
Founded in 2006 and based in Tres Cantos city (Madrid, Spain) ProAlt is a biotechnology company focused on the development and commercialization of (i) biomarker-based assays for cancer diagnosis and clinical management and (ii) therapeutic monoclonal antibodies against novel targets aimed for the treatment of highly aggressive colon, breast and melanoma tumors. The company also offers its (iii) own manufactured innovative recombinant proteins and antibodies, and different custom-tailored integral services in protein design, expression and purification. Service offer is performed under individual customer contracts (CRO/CMO) to meet customers needs.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.